Protease inhibitor frequencies: is there a deficit of M subtype heterozygotes?
A large number of reports on human protease inhibitor (PI) type frequencies in various populations have now appeared. A combination of the results of published studies shows that the observed frequencies of the M subtype homozygotes and heterozygotes differ significantly from those predicted by the Hardy-Weinberg equilibrium, especially among Europeans but probably not among Asians or Africans. The M1, M2 and M3 homozygotes are more numerous than would be expected, while the M1M2 and M1M3 heterozygotes are less common than expected.
Whitfield
J B
JB
Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
D000349:Africa / Q000453:epidemiology; D001208:Asia / Q000453:epidemiology; D005060:Europe / Q000453:epidemiology; D005787:Gene Frequency / Q000235:genetics*; D006580:Genetic Carrier Screening / Q000379:methods*; D006720:Homozygote; D006801:Humans; D015201:Meta-Analysis as Topic; D010641:Phenotype; D011480:Protease Inhibitors / Q000032:analysis*
D011480:Protease Inhibitors